Milind Javle, MD - Embracing the Era of Individualized Therapy in Advanced Biliary Cancers: Expert Strategies for Applying New and Emerging Targeted Treatment Options Through Precision Medicine

Go online to PeerView.com/DRJ860 to view the activity, download
slides and practice aids, and complete the post-test to earn
credit. Are you prepared to bring modern approaches to the
treatment of patients with biliary cancers to your clinical
practice? Learn how the treatment paradigm is shifting from
conventional chemotherapy to biomarker-guided treatments and
immunotherapy in a new event from PeerView and the
Cholangiocarcinoma Foundation. Our experts will offer learners a
deep dive into the latest science on the biologic rationale for
targeting prevalent genetic aberrations in biliary cancers and
review key safety and efficacy data from recent pivotal clinical
trials of novel strategies. Through discussions of relevant patient
scenarios, our panel will offer insight on how to integrate
biomarker-guided treatments into clinical practice and practical
guidance on identifying patients with advanced biliary cancers who
are eligible for targeted treatment. Upon completion of this CE
activity, participants will be able to: Summarize the rationale for
use and recent efficacy and safety data on newly available and
emerging therapeutic strategies for patients with advanced biliary
cancers, including FGFR, IDH, TRK, multikinase, HER2, and immune
checkpoint inhibitors, Identify patients with advanced biliary
cancers who are eligible for treatments with available and emerging
therapies targeting FGFR genomic aberrations, multikinase tumor
pathways, HER2 alterations, NTRK gene fusions, IDH1/2 mutations,
and immune checkpoint pathways, Integrate the latest clinical
evidence into the management of patients with advanced biliary
cancers, utilizing molecular testing and established and emerging
targeted options based on individual tumor characteristics in the
context of clinical practice or a clinical trial.